Explore

Communities in English

Advertise on Engormix

Recombinant Viral Vector Vaccines

Issues of the Poultry Recombinant Viral Vector Vaccines which May Cause an Effect on the Economic Benefits of those Vaccines

Published: September 16, 2011
By: Rudolf G. Hein, Consultant Microbiologist
Summary
Over the last decennia different recombinant viral vector vaccines for poultry have been introduced in several countries.
The first vaccines were all based on the Fowl pox(FP) virus  used as the vector (e.g. the avian influenza (AI) recombinant (r) FP/H5, NewcastleDisease (ND) rFP/ND, infectiouslaryngotrachetis (ILT) rFP/ILT vaccines. The most recent ("second generation") viral vector vaccines introduced are based onthe herpes virusofturkeys(HVT) vector like the recombinant(r) HVT/(ND), rHVT/ILT, rHVT/Infectious Bursal Disease (IBD) and the rHVT/H5(AI) vaccines.
These novel vaccines in particular the rHVT vector vaccines have shown to be of an economic benefit for the poultry industry compared with the conventional vaccines.  However failures due to several issues inherent on these vaccines have been observed.  The different issues and its control to prevent those failures will be discussed. 
Key words: recombinant viral vectored vaccines, fowl pox virus ,herpesvirus of turkeys.
The first generation of recombinant viral vector vaccines based on the FP vector like the rFP/ILT showed applied at 8-10 weeks by the wingweb route an improvement in the control of ILT compared with the conventional live ILT vaccines.
However the disadvantages of the FP vector vaccines are the rather short duration of protection in long lived birds in contrast to the "live long" protection obtained with the HVT vector vaccines(8,9) due to the persistent nature of the HVT vector.In addition FP virus maternal antibodies (Mab) may interfere with the onset of immunity in chickens vaccinated at an early age  and a "no take" of the FP vector vaccine will occur  in birds previously vaccinated or infected with FP. Other question of concern is the safety of the FP vector vaccines administrated in ovo (15) 
Most of the FP virus vector vaccines will be over time replaced by the much more advantageous HVT vector vaccines.
The rHVT/ND,ILT and IBDV vector vaccines have clearly shown to be efficacious, improving the performance of the vaccinated flocks, consequently providing economical benefits to the poultry industry compared with the conventional live ND,ILT and IBD and inactivated ND vaccines used to control respectively ND or ILT or IBDV.(4,6,11,12,14).
Several issues inherent on these vaccines have shown specifically under field conditions  to play a role in the failures of the efficacy of these novel vaccines.(5) Although most of these issues can  easily  be prevented to avoid these type of failures.
With the focus on the rHVT vector vaccines the isssues and how  prevent these issues will be in detail discussed in this presentation:
Application/Administration
The rHVT vector vaccines are like the HVT vaccines applied subcutaneously at one day of age or administrated in ovo in the hatchery. The rHVT vector (similar as the HVT vaccines) does not spread,any non vaccinated/missed chicken will not be protected. Even in the case of very small number of "missers" in an endemic area a negative effect on the efficacy can be observed.(5,17).
 Particular in highly endemic areas, any errors in the subcutaneous application at one day of age or the in ovo administration plays an important role in failing to provide optimal protection.
Proper application is one of the main important issue in the success of these novel vaccines.
Onset of Immunity
Complete protection(>90%) against the expressed ed foreign gene antigens of the rHVT vector vaccines is not achieved untill  approximately 3-4 weeks of age.
High uniform Mabs in for NDV in rHVT/ND  and for  IBDV in  rHVT/IBD vaccinated birds  have shown to minimize the effect of the delay in onset of immunity (4,11)
In (v)ND endemic locations a live  safe conventional ND vaccine is recommended at one day of age to provide the early protection for ND.(4,12,13,14)
Protection against MD
It has been shown that with the rHVT vector constructs  the  level of  protection against MDV may be compromised in comparison with the parent strain in the case of virulent Marek''''s Disease virus(MDV) exposure at an early age.(MDV shedder trials).Combining the rHVT vector vaccines with the serotype1MDV CVI988 (Rispens strain) or serotype 2 MDV SB1 same level of protection has been observed in comparison with HVT+CVI988 or HVT+SB1.(3,6)
Compatibility rHVT vector vaccines and with other MDV vaccines
Simultaneously vaccinating or combining different rHVT vector vaccines will result in the interference of expressing the ed foreign gene antigen of one of the rHVT vector vaccines.This interference is most likely expressed as an extended delay of the onset of immunity of one of the combined rHVT vector vaccines.
Combining rHVT vector vaccines with conventional HVT vaccines to improve e.g. MD protection  will have a serious negative  effect on the efficacy of the rHVT vector vaccine(2,16) 
Persistence and possible transmission of the challenged virulent virus in rHVT vector post challenged vaccinated birds
In laboratory trials chickens vaccinated in ovo or by the subcutaneous route at one day of age  with the rHVT/ILT and challenged at 4-5 weeks of age no reduction of the  replication  of  the challenge virus in the upper respiratory tract for a short period of time  even in birds without any clinical symptoms was observed.(1,6,9).In vNDV challenged birds simultaneously vaccinated with the rHVT/ND and a live  ND vaccine a significantly reduction of  the challenge virus dose in the trachea was observed  in contrast to the birds vaccinated with the recombinant alone (12)
However  the transmission of the challenge virus to susceptible birds has yet  not been shown.(Rosenberger pers.comm.2011)
Additional issues not specific related to the rHVT vaccines are immunosupprsion , chick quality etc
Conclusion
The success of these novel rHVTviral vector vaccines  largely depends on:  
a) Proper application of the recombinant HVT viral vector vaccines by the subcutaneous route at one day of age or by the in ovo administration.
b) High uniform NDV and IBDV Mabs derived from properly vaccinated parent stock will reduce the effect of the delay in the onset of complete protection in chickens vaccinated with the rHVT/ND or rHVT/IBDV vector vaccines. In addition in vND endemic areas a live ND vaccination at one day of age is required.
c) Combining the rHVT viral vector vaccines with MDV SB1 or  CVI988 vaccine in high risk MDV areas.
d) Avoid combining different recombinant viral  vector vaccines or simultaneously vaccination with any conventional live vaccine not recommended by the manufactory.
References
1.Garcia,M.,G Zavala,A.Vagnozzi,S.M.Riblet and A.Mundt.Evaluation of the protection induced by commercial available fowl poxvirus(FPV) and herpesvirus of turkey HVT viral vector vaccines against infectious laryngotracheitis(ILT) in broilers. Proc.1st International Avian Resp. Dis.Conf. Athens USA 42 2011
2.Godoy,A.,M.Esaki,P.Flegg,J.Rosenberger,S.Rosenberger,K.M.DorseyandY.Gardin. Compatibility of vectored LT vaccines and Vectormune HVT NDV. AAAP Conf.St Louis 2011
3.Hein,R.G. and G.Slacum.Efficacy against Very Virulent(vv) Marek''''s Disease Virus (MDV) of the HVT/ND Recombinant (Innovax-ND-SB) and the Immunity against Virulent(v)Newcastle Disease Virus(NDV). Proc. 56th Western Poultry Dis. Conf Las Vegas USA 83 2007
4Hein,R.G.,J.F.Rios,A.Aguilera and J.Domhof.Newcastle Disease(ND) Efficacy in Broilers Vaccinated at One Day of Age with the Recombinant HVT/F(ND):INNOVAX-ND-SB
Challenged with the Mexican vND virus isolate Chimalhuacan.Proc.75th Western Poultry Dis.Conf.Puerto Vallarta Mexico pg32-33 2008.
5.Hein,R.,G.Slacum,P.Lynch and K.Honegger.Recombinant HVT/ILTV Vaccine(INNOVAX-ILT) Field Application Issues  Proc.43rd. Nat.Meeting on Poultry Health and Processing Ocean City Md.73 2008.      
6.Hein,R.,Novel HVT/ILT Recombinant Vaccine to Simultaneously Control Infectious Laryngotracheitis and Marek''''s Disease in Chickens(INNOVAX-ILT).Proc.VI Int.Symposium on Avian Corona and Pneumoviruses Rauschholzhausen Germany 385-386 2009 
7.Johnson,D.,A.Vagnozzi,F.Dorea,S.M.Riblet,A.Mundt,G.Zavalla. Protection Against Infectious Laryngotracheitis by In Ovo Vaccination  with Commercially Available Viral Vector Recombinant Vaccines. Avian Dis.54:1251-1259,2010.
8.Melson,L and K.Jensen, Duration of Immunity in Chickens Following Vaccination with a Recombinant Herpesvirus of Turkeys Vaccine Expressing the Fusion(F) Antigen of Newcastle Disease Virus. Proc.1st International Avian Resp. Dis.Conf. Athens USA 59 2011
9.Melson,L and K. Jensen, Duration of Immunity in Chickens Following Vaccination with a Recombinant Herpesvirus of Turkeys Vaccine Expressing Infectious Laryngotracheitis Antigens. Proc.1st International Avian Resp. Dis .Conf. Athens  USA  65 2011.
10.Morgan,R.W.,J.Gelb,C.S.Schreurs,D.Lutticken,J.Rosenberger, P.J.Sondermeijer .Protection of Chickens from Newcastle and Marek''''s Disease with Recombinant Herpesvirus of Turkeys Vaccine Expressing the Newcastle Disease Virus Fusion Protein. Avian Dis.36: 858-870 1992.
11.Le Gros,F.X.IBD Efficacy data in presence of Maternal Antibodies in Broilers and Layers with a Novel Vector HVT-IBD vaccine. Proc.VI Int. Symposium on Avian Corona and Pneumoviruses  Rauschholzhausen Germany 376-384 2009   
12.Palya,V.,Z.Penzes,T.Horvath,V.Kardi,K.Moore and Y.Gardin. Comparative Efficacy of Several Vaccination Programs including or not including Recombinant HVT-ND Vaccine against Challenge with Mexican Chimahuacan NDV strain. Proc.75th Western Poultry Dis.Conf.Puerto Vallarta Mexico pg36-38 2008.
13.Rauw,F.,YGardin,V.Palya,S.Anbari,S.Lemaire,M.Boschmans,T.v.d.Berg and B.Lambrecht.
Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day old. Vaccine vol. 28 823-833 2010.
14.RiosJ.F. and R.G.Hein. Field Evaluation of a Recombinant rHVT/NDV vaccine in Broilers in a vNDV Region in Mexico.Proc .Western Poultry Dis. Conf. Vancouver Canada pg32-34 2010.
15.Rosenberger,J.K.andS.C. Rosenberger ,ILT Vaccines Field and Laboratory Assessments.
Proc.41st Nat. Meeting on Poultry Health and Processing Ocean City Md.81-85 2006.
16.Slacum,G.,R.G.Hein and P.Lynch The Compatibility of Recombinant HVT vaccines and other MD vaccines .Proc. 76th Western Poultry Dis.Conf.Sacramento 2009.
17.Williams,C.J. and B.A. Hopkins,field evaluation of the accuracy of vaccine deposition by two different commercially available in ovo injection systems.Poultry Science 90.223-226 2011 
This paper was presented at the XVII World Veterinary Poultry Association (WVPA) Congress in Cancún, Mexico, August 14-18, 2011. Engormix.com thanks the author and the organizing committee for this huge contribution. 
Related topics:
Authors:
Rudolf Hein
Influencers who recommended :
Surinder Maini, DR.R.N.Sreenivas Gowda
Recommend
Comment
Share
Rudolf Hein
8 de junio de 2021
I agree with comments made by Michel Bublot Mixing any recombinantHVT vector vaccine with a conventional HVT vaccine will interfere with the protection of the insert like in your case with the AI/H5 protection As mentioned will not effect the MD protection To improve protection of the recombinant for MD you can if manufacture recommend to combine the recombinant HVT vector vaccine with SB1 or Rispens
Recommend
Reply
Michel Bublot
7 de junio de 2021
It is the HVT in the first HVT+SB1 vaccine that will interfere on the avian influenza H5 protection induced by the rHVT-H5 in the boost. The Marek's disease protection should be similar as if birds had received two times HVT+SB1 since rHVT-H5 is an HVT. So, Marek's protection should be the same but H5 protection will not be at the expected level.
Recommend
Reply
Gary Butcher
University of Florida
University of Florida
17 de octubre de 2011

Excellent paper about poultry health. Well balanced and practical. Gary Butcher

Recommend
Reply
Maqsood Jaffery
11 de octubre de 2011
It is really informative article about Recombinant Viral Vector Vaccines . Author has given details about failure of immunity development. It should be helpfullfor better protection through taking care of factors affecting development of immunity. As vector vaccines develop humoral immunity response (antibodies), so by give conventional live vaccine for same particular vector vaccine will give local immunity through cellular immunity process. It shall be helpfull for inhibting the replication of challange virus. As these vaccines are new, all valuable informations/ inputs will be helpful for all the concrned of poultry health. Regards, Maqsood Jaffery
Recommend
Reply
Surinder Khanna
8 de junio de 2021
I feel if we do not combine rhtv with md and sb1 strain same day but post phone it 2 days later , it should not reduce titres of avian influenza?
Recommend
Reply
Dr. Sanjeev Kumar Sharma
8 de junio de 2021
Very nice info. Q & A
Recommend
Reply
Puneet Jindal
25 de mayo de 2021

Sir in India, live bivalent vaccine ( hvt1 + Sb1) is administered at hatchery level engaged in providing layer chicks. Then at layer poultry farm, this vaccine is repeated as booster for control of Marek disease at day 1/2. Now if we give avian influenza vector vaccine Rhvth5 at day 3, then won't rhvt5 for avian influenza interfere with bivalent live vaccine for Marek? Please advise.

Recommend
Reply
Dr.Munawar Hasan
Dr.Munawar Hasan
14 de octubre de 2011

I found this article about poultry health is very informative specially the possible causes of failure and precautions for avoiding the failure of the vaccine.

Regards.

Recommend
Reply
Dr Muhammad Arshad  Manj
SB Feed
12 de octubre de 2011

Aoa, an informative article about poultry health but why is it suggested to inject at day one bcs at day one it is very difficult to inject the bird

Recommend
Reply
Profile picture
Would you like to discuss another topic? Create a new post to engage with experts in the community.
Featured users in Poultry Industry
Padma Pillai
Padma Pillai
Cargill
United States
Kendra Waldbusser
Kendra Waldbusser
Pilgrim´s
United States
Karen Christensen
Karen Christensen
Tyson
Tyson
PhD, senior director of animal welfare at Tyson Foods
United States
Join Engormix and be part of the largest agribusiness social network in the world.